- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00340899
Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study
February 22, 2023 updated by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Restriction: A Longitudinal Study
Preterm delivery, preeclampsia and intrauterine growth restriction are leading causes of perinatal morbidity and mortality.
Efforts to treat these syndromes have not been effective, most likely becuase these obstetric complications are the clinical expression of adaptive mechanisms of host defense developed in response to pathologic insults.
Since the ultimate pathologic basis of disease is unclear, therapy for these syndromes has been largely directed at symptoms, which appear late in the development of the disease.
The main purpose of this study is to perform an early and comprehensive exploration of maternal and fetal factors that predict the subsequent develpment of these obstetrice complications, so that early medical interventions may be tested in patients at high and low risk for adverse perinatal outcome.
Study Overview
Status
Completed
Conditions
Detailed Description
Preterm delivery, preeclampsia and intrauterine growth restriction are leading causes of perinatal morbidity and mortality.
Efforts to treat these syndromes have not been effective, most likely because these obstetric complications are the clinical expression of adaptive mechanisms of host defense developed in response to pathologic insults.
Since the ultimate pathologic basis of disease is unclear, therapy for these syndromes has been largely directed at symptoms, which appear late in the development of the disease.
The main purpose of this study is to perform an early and comprehensive exploration of maternal and fetal factors that predict the subsequent development of these obstetric complications, so that early medical interventions may be tested in patients at high and low risk for adverse perinatal outcome.
Study Type
Observational
Enrollment (Actual)
19134
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Santiago, Chile
- Sotero del Rio Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 45 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Pregnant women attending prenatal clinics
Description
- INCLUSION CRITERIA:
- Gestational age between 6 and 22 weeks for the first visit based on the patient s last menstrual period as reported by the patient.
- High risk group: presence of specific risk factors for preterm delivery, pregnancy-induced hypertension or intrauterine growth retardation.
- Low risk group: normal pregnancy with no risk factors for preterm delivery, pregnancy-induced hypertension or intrauterine growth retardation (control population, selected between 6 and 22 weeks at the prenatal care clinic). The rationale to include this group is that 50-70% of preterm deliveries occur in patients without risk factors for preterm birth.
- Consent to participate in the study.
- Patient should be able to attend each Perinatal Research Center for prenatal care and participation in this study.
EXCLUSION CRITERIA:
- Preterm labor, preterm PROM, preeclampsia or impaired fetal growth at the time of recruitment.
- Any maternal or fetal condition that requires termination of pregnancy.
- Known major fetal anomaly or fetal demise.
- Active vaginal bleeding.
- Multifetal pregnancy with greater than or equal to 3 fetuses.
- Serious medical illness (renal insufficiency, congestive heart disease, chronic respiratory insufficiency, etc).
- Severe chronic hypertension (requiring medication).
- Asthma requiring systemic steroids.
- Patient requiring anti-platelet or non-steroidal anti-inflammatory drugs.
- Active hepatitis.
- Lack of consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Pregnant women
Pregnant women with gestational age between 6 and 22 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Preterm delivery
Time Frame: Ongoing
|
Preterm delivery will be classified according to the immediate clinical antecedent of delivery (spontaneous preterm labor with intactmembranes, preterm premature rupture of membranes and pretermdelivery for maternal or fetal indications).
|
Ongoing
|
|
Preeclampsia
Time Frame: Ongoing
|
Preeclampsia will be defined according to the following criteria:-Systolic blood pressure greater than or equal to 140 mmHg and/or diastolic blood pressure greater than or equal to 90 mmHg on twooccasions greater than or equal to 6 hours apart.-Proteinuria
greater than or equal to 300 mg/24 hr or freater than or equal to 2+ (dipstick) on two occasions greater than or equal to 6 hours apart.-The
diagnosis of severe preeclampsia will be made in the presence of any of the following: blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 110 (diastolic) on at least two occasions, proteinuria greater than or equal to 5 gr /24 hr, pulmonary edema, thrombocytopenia, oliguria, neurologic symptoms(headache, visual disturbances, persistent hyperreflexia, upperabdominal pain and HELLP syndrome).
Eclampsia will be diagnosed if convulsions develop.
|
Ongoing
|
|
Intrauterine growth restriction
Time Frame: Ongoing
|
Intrauterine growth retardation / small for gestational age infantA small for gestational age fetus will be considered that with a birth weight which is below the 10th percentile for gestational age.
Additional cutoffs (5th and 3rd percentile) will also be explored.
|
Ongoing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Pollack RN, Divon MY. Intrauterine growth retardation: definition, classification, and etiology. Clin Obstet Gynecol. 1992 Mar;35(1):99-107. doi: 10.1097/00003081-199203000-00015. No abstract available.
- Romero R, Mazor M, Wu YK, Sirtori M, Oyarzun E, Mitchell MD, Hobbins JC. Infection in the pathogenesis of preterm labor. Semin Perinatol. 1988 Oct;12(4):262-79. No abstract available.
- Harding JE, Owens JA, Robinson JS. Should we try to supplement the growth retarded fetus? A cautionary tale. Br J Obstet Gynaecol. 1992 Sep;99(9):707-9. doi: 10.1111/j.1471-0528.1992.tb13866.x. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 4, 1997
Primary Completion (Actual)
July 3, 2017
Study Completion (Actual)
July 13, 2017
Study Registration Dates
First Submitted
June 19, 2006
First Submitted That Met QC Criteria
June 19, 2006
First Posted (Estimate)
June 21, 2006
Study Record Updates
Last Update Posted (Actual)
February 24, 2023
Last Update Submitted That Met QC Criteria
February 22, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 999997067
- OH97-CH-N067
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Birth
-
Shaare Zedek Medical CenterTerminatedPremature Birth of NewbornIsrael
-
Case Western Reserve UniversityCompleted
-
University of VirginiaCompletedPremature Birth of NewbornUnited States
-
University of California, San FranciscoUniversity of California, San Diego; University of California, Los Angeles; Kaiser...CompletedPremature Birth of NewbornUnited States
-
Universidad Complutense de MadridCompletedPremature Birth of Newborn
-
Elgan Pharma Ltd.Terminated
-
Hôpital de la Croix-RousseUnknownPremature Birth of NewbornFrance
-
Carmen Rosa PallasHospital Universitario 12 de OctubreUnknown
-
Washington University School of MedicineCompleted
-
Indiana UniversityCompletedPremature LaborUnited States